MarketBeat estimates USD 1.00 million revenue for Curis stock

Published on 10/24/2026 at 20:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash stood at USD 5.1 million on June 30, 2026, while December clinical data remain planned. Curis stock costs EUR 0.35 on October 24, 2026.

Revenue estimate and cash position

MarketBeat estimates Curis revenue at USD 1.00 million for the third quarter of 2026.
Curis reported USD 5.1 million in cash and equivalents as of June 30, 2026.
Curis stock costs EUR 0.35 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

CRIS, US2312694084, Illustration mit AI erstellt.

Curis (ISIN US2312694084) is covered by a third-quarter 2026 revenue estimate of USD 1.00 million, down from USD 3.18 million in the year-earlier quarter. MarketBeat published the estimate on October 23, 2026, putting the implied decline at 68.55 percent. Curis stock was priced at EUR 0.35 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Revenue estimate sets the next test

The estimate gives investors a concrete benchmark for the company's third-quarter update. MarketBeat lists consensus earnings per share at minus USD 2.29 and revenue at USD 1.00 million for the third quarter of 2026, compared with a loss of USD 9.80 per share and revenue of USD 3.18 million in the same quarter a year earlier.

Curis develops cancer therapies centered on emavusertib, an oral IRAK4 and FLT3 inhibitor. The company's investor-relations page identifies emavusertib as its lead development program and lists Curis as a Nasdaq company.

Cash position and clinical timing

Curis reported cash and equivalents of USD 5.1 million as of June 30, 2026, while operating cash flow was negative USD 9.6 million in the second quarter. The figures point to a funding-sensitive development model as the company advances clinical work.

In a filing dated October 16, 2026, Curis agreed to sell 16,666,680 shares or pre-funded warrants and warrants covering up to 16,666,680 additional shares at an effective price of USD 0.51 per share. The filing said proceeds of USD 8.5 million were intended to fund research, working capital and operations through initial chronic lymphocytic leukemia data in five to 10 patients in December 2026, subject to the offering closing. StockTitan carried the filing details.

Trading frame for Curis

Curis had a market capitalization of USD 0.8 million and a 52-week range of USD 0.33 to USD 33.00 as of October 23, 2026. The Nasdaq-listed biotechnology company is therefore trading close to the lower end of that range in its home-market quotation, while the German euro quote provides the current local trading reference.

The next reported period is the third quarter of 2026. The company said the December clinical milestone concerns initial chronic lymphocytic leukemia data, while the revenue estimate remains the nearer financial benchmark for the stock.

Market context

Curis was trading at EUR 0.35 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Curis stock.